Answers are grounded in this paper and cite their sources.
Background and Aims In the SYNERGY-NASH trial in metabolic dysfunction-associated steatohepatitis (MASH) and stage 2 or 3 fibrosis, tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, effectively resolved MASH without worsening fibrosis in up to 73% of patients. We explored the extent of histological improvements across clinically relevant subgroups in this trial. Methods Participants (n=190) were randomly assigned 1:1:1:1 to receive once-weekly s.c. tirzepatide (5, 10, or 15 mg) or placebo for 52 weeks. We analyzed 155 participants who completed the study on treatment with evaluable end-of-treatment biopsies. Post-hoc subgroups (n=34) were defined by demographics, histology, serum, and imaging biomarkers using the median of baseline values for continuous variables. Risk differences (RDs) versus placebo (95% CI) were calculated using a logistic regression model. Results Compared with placebo, tirzepatide was consistently associated with improved MASH resolution without worsening fibrosis across subgroups of sex, age, ethnicity, body mass index, type 2 diabetes status, histological disease activity, fibrosis stage, serum aminotransferases, serum biomarkers of fibrosis and MASH, and imaging assessments of liver fat, fibroinflammation, and stiffness. For tirzepatide 5, 10 and 15 mg, the RDs were significant (p<0.05 or lower) for 74%, 97%, and 100% of the subgroups, respectively. While most RDs for fibrosis improvement without worsening of MASH favored tirzepatide, these were not statistically significant in 59-79% of the subgroups due to limited sample size. Significant (p<0.05) fibrosis improvement was observed with tirzepatide 5 and 15 mg among participants with stage 3 fibrosis. Conclusion These post-hoc analyses suggest that tirzepatide was consistently associated with improved MASH resolution without worsening of fibrosis across subgroups defined by demographics, histology, and biomarkers, as compared with placebo. SYNERGY-NASH ClinicalTrials.gov number: NCT04166773
No takes yet. Share an insight, caveat, or question.
Hartman et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: